Skip to content

Nasdaq · CIK 0001787297

PASG Passage BIO, Inc.

Insider trading from SEC Form 4. Last filing Mar 18, 2025. Close $3.69 on Oct 9, 2026, 0% from the 52-week low and -81% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company

Price and insider trades, last year

PASGOct 9, 2026 · close 3.69

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Passage BIO, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
7WeakKathleen Borthwick
CFO
sell
$1,686
3,183 shares
-7%-
25WeakLynx1 Capital Management LP
owner
buy
$241k
373,645 shares
+4%-
23WeakOrbimed Advisors LLC
owner
sell
$138k
230,321 shares
-3%-
19WeakOrbimed Advisors LLC
owner
sell
$52k
62,276 shares
-1%-
20WeakOrbimed Advisors LLC
owner
sell
$77k
97,103 shares
-1%-
24WeakLynx1 Capital Management LP
owner
buy
$285k
456,353 shares
+5%-

Transactions

The last 16 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 15, 2025Kathleen Borthwick
CFO
AGrant or award
Employee Stock Option (right to buy)derivative
+278,386$0.00$0278,386Mar 18, 2025
Mar 15, 2025Edgar B. Cale
GC & CORPORATE SECRETARY
AGrant or award
Employee Stock Option (right to buy)derivative
+278,386$0.00$0278,386Mar 18, 2025
Mar 15, 2025William Chou
PRESIDENT AND CEO
AGrant or award
Employee Stock Option (right to buy)derivative
+779,533$0.00$0779,533Mar 18, 2025
Feb 10, 2025Kathleen Borthwick
CFO
MOption exercise
Common Stock
+8,000--44,466Feb 12, 2025
Feb 11, 2025Kathleen Borthwick
CFO
SOpen-market sale
Common Stock
-3,183$0.53$1,68641,283Feb 12, 2025
Feb 10, 2025Kathleen Borthwick
CFO
MOption exercise
Restricted Stock Unitderivative
-8,000$0.00$00Feb 12, 2025
Dec 27, 2024Lynx1 Capital Management LP
owner
POpen-market purchase
Common stock, $0.0001 par value per shareindirect: See footnote
+373,645$0.65$241k9,256,953Dec 31, 2024
Dec 20, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-230,321$0.60$138k7,404,869Dec 26, 2024
Dec 9, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-54,181$0.84$46k7,643,285Dec 11, 2024
Dec 10, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-8,015$0.80$6,4127,635,270Dec 11, 2024
Dec 11, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-80$0.80$647,635,190Dec 11, 2024
Dec 4, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-76,200$0.79$60k7,718,369Dec 6, 2024
Dec 6, 2024Orbimed Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See footnotes
-20,903$0.82$17k7,697,466Dec 6, 2024
Nov 25, 2024Lynx1 Capital Management LP
owner
POpen-market purchase
Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote
+259,998$0.56$147k8,686,953Nov 27, 2024
Nov 26, 2024Lynx1 Capital Management LP
owner
POpen-market purchase
Common Stockindirect: See footnote
+167,055$0.71$118k8,854,008Nov 27, 2024
Nov 27, 2024Lynx1 Capital Management LP
owner
POpen-market purchase
Common Stockindirect: See footnote
+29,300$0.67$20k8,883,308Nov 27, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

PASG insider trading: Passage BIO, Inc. | InsiderTell